Richard Gorlick
Leader and Core Director · University of Texas M D Anderson Cancer Center
Credentials: · · ·
History
- 1991–1994
Hematology and Medical Oncology
Research
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Review · Journal of Clinical Oncology · 2015 · Last of 4 authors · Corresponding · 1,275 citations
Advancing therapy for osteosarcoma
Review · Nature Reviews Clinical Oncology · 2021 · 673 citations
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
Nature Medicine · 2004 · 562 citations
- EK
88 papers · 2 as a fellow
- MS
82 papers
71 papers
- PM
64 papers
51 papers
47 papers · 5 as a fellow
42 papers
41 papers
Grants
- 2025–2030
National Cancer Institute · P50
Contact PI · $3.6M · University of Tx Md Anderson Can Ctr
- 2015–2027
Genomically Informed Agent Selection and Testing in Osteosarcoma Patient-Derived Xenograft Models
National Cancer Institute · U01
Contact PI · $3.8M · University of Tx Md Anderson Can Ctr
- 2005–2010
Molecular Targeting of Developmental Cancers in Children
National Cancer Institute · P01
Project lead · $1M · Sloan-Kettering Inst Can Research
- 1999–2008
Antifolate Resistance in Osteosarcoma
National Cancer Institute · R01
Contact PI · $1M · Albert Einstein College of Medicine
Clinical trials
- 2012–2018
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
Principal investigator · Completed · Phase 2
Eleison Pharmaceuticals LLC.
- 2010
Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma
Principal investigator · Completed
Children's Oncology Group
- 2008–2023
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
Principal investigator · Completed
Children's Oncology Group
- 1999–2003
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
Study chair · Completed · Phase 2
Memorial Sloan Kettering Cancer Center